De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.
about
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationMS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.The use of natalizumab for multiple sclerosisProgress in multiple sclerosis research in the last year.Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?Multiple sclerosis imaging: recent advances.Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Fingolimod after natalizumab and the risk of short-term relapse.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Monoclonal antibodies in treatment of multiple sclerosis.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.Disease activity return after natalizumab cessation in multiple sclerosis.Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.What to expect after natalizumab cessation in a real-life setting.Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.Switching therapies in multiple sclerosis.Incorporating real-world clinical practice in multiple sclerosis economic evaluations.Recurrence of disease activity after repeated Natalizumab withdrawals.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.[Current aspects of therapy conversion for multiple sclerosis].Significant clinical worsening after natalizumab withdrawal: Predictive factorsIntense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report
P2860
Q30699740-BAE90858-919B-4672-928F-EAA73ECD05EBQ33562198-B92692A2-3C84-4EC2-AB8F-F760EFC3D9EAQ33571905-1017D85C-5137-4955-B4A0-D433FDDC86DEQ33736193-8F20C9D9-34F7-46E3-ACFB-ABE5337E08E0Q33879159-E60BA9B0-B453-4BDE-B928-70C918A2A3EDQ34313311-450FC98B-D9BB-450A-BF5B-C026721E6320Q34365360-BC44ABCE-E789-45DF-AB18-9799C83A33C9Q34522015-A4A8DBF4-63DA-4360-908C-BADF89CF5DEFQ34893972-3B61760F-A405-48E2-B8CC-56C8465397E1Q35862875-30C9E6A4-1DE2-4C97-85B7-04430BA706C4Q36389681-9C3D8F29-F5F1-46A6-823E-724E657F8C63Q36975701-C612B8ED-AB6E-4057-8BBC-77828240A4C4Q37045253-25631E68-B761-4789-BDD5-99402A611A1FQ37725909-54BAF6C5-3C50-48BB-86E8-674BE23BC2F9Q38117110-6A8733DC-14CF-4FA5-8252-58F6BEAB3E83Q38133865-1CE69790-3935-4140-9E22-A4F882B85430Q38152451-BDAD9481-C50F-46D0-AEA8-4DBDE976010AQ38177842-471C2F1D-A2C4-4F1E-9838-5EE58DCB772FQ38619288-1B3BA8CE-E629-43AB-B0F8-7789B00FCEE5Q38779091-40FF43C3-54D2-45E0-86FC-8468B726851EQ39711019-94D87C7D-1BF8-492F-88FC-89D12D43536BQ41369754-CF5FE733-7D84-4956-8EE9-3645FE0509D4Q41626879-B528717D-4432-47A5-B3D9-B5BFF9B8B221Q44012129-A3797CF6-AE6D-4340-A43B-D6A410EDE062Q44840261-ABF6E46E-31BD-4A5C-A584-59D370E65F37Q45921292-2C4C84EF-3B4F-4E5A-975A-731AEC576739Q45977173-FA3B2F35-48D5-478F-8EEE-0C227E1277A4Q50976326-50033321-6211-47D6-9FF9-1200142A688FQ51051036-C7559CA0-C8E2-4650-921D-70027649CF25Q51218322-DF70848F-F179-4F81-A717-6E4178389A4EQ51247242-946A29EF-340D-448F-9EDA-4D54479A733FQ53582374-40ABA4B5-F9B0-4EF2-B9A7-55049E5CDD9DQ57601805-BA9124AB-3B62-405A-BE70-7CB219CA8B7CQ57913814-5E782D5F-C77C-4048-AEC5-A857FB11EF51
P2860
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
De-escalation from natalizumab ...... itching to glatiramer acetate.
@en
De-escalation from natalizumab ...... itching to glatiramer acetate.
@nl
type
label
De-escalation from natalizumab ...... itching to glatiramer acetate.
@en
De-escalation from natalizumab ...... itching to glatiramer acetate.
@nl
prefLabel
De-escalation from natalizumab ...... itching to glatiramer acetate.
@en
De-escalation from natalizumab ...... itching to glatiramer acetate.
@nl
P2093
P2860
P1433
P1476
De-escalation from natalizumab ...... itching to glatiramer acetate.
@en
P2093
Frank Weber
Hannah Luise Pellkofer
Hans Faber
Ingrid Meinl
Joachim Havla
Lisa Ann Gerdes
Markus Krumbholz
Reinhard Hohlfeld
Tania Kümpfel
P2860
P2888
P304
P356
10.1007/S00415-011-5996-Y
P577
2011-03-23T00:00:00Z